61.69

2.65% 1.59

After Hours: 60.26 -1.43 -2.32%

Exact Sciences Corp (EXAS)

Overview News Price History Option Chain Financials Discussions Forecast

Exact Sciences Corp stock is traded at $61.69, with a volume of 2.49M. It is up +2.65% in the last 24 hours and down -10.74% over the past month. Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Previous Close:

$60.10

Open:

$60.41

24h Volume:

2.49M

Relative Volume:

0.94

Market Cap:

$11.23B

Revenue:

$2.69B

Net Income/Loss:

$-214.04M

P/E Ratio:

-38.90

EPS:

-1.5857

Net Cash Flow:

$98.43M

1W Performance:

+17.06%

1M Performance:

-10.74%

6M Performance:

+23.78%

1Y Performance:

-6.27%

1-Day Range:

$59.87

$61.95

1-Week Range:

$52.17

$61.95

52-Week Range:

$40.62

$79.62

Exact Sciences Corp Stock (EXAS) Company Profile

Name

Exact Sciences Corp

Sector

Healthcare (1200)

Industry

Diagnostics & Research (57)

Phone

608-284-5700

Address

5505 ENDEAVOR LANE, MADISON, WI

Employee

6,600

Twitter

@exactsciences

Next Earnings Date

2024-11-05

Latest SEC Filings

EXAS's Discussions on Twitter

Compare EXAS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXAS Exact Sciences Corp	61.69	11.23B	2.69B	-214.04M	98.43M	-1.5857
TMO Thermo Fisher Scientific Inc	521.66	199.82B	42.37B	6.14B	7.78B	15.26
DHR Danaher Corp	238.83	173.66B	23.74B	3.89B	4.98B	7.93
A Agilent Technologies Inc	138.14	38.64B	6.51B	1.29B	1.37B	3.82
IQV Iqvia Holdings Inc	201.43	36.52B	15.32B	1.41B	1.96B	5.95
IDXX Idexx Laboratories Inc	421.76	34.55B	3.84B	866.24M	792.60M	9.80

Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-28-24	Initiated	Wells Fargo	Overweight
Jun-27-24	Initiated	Scotiabank	Sector Outperform
Jun-03-24	Resumed	Jefferies	Buy
Jan-02-24	Upgrade	The Benchmark Company	Hold → Buy
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Oct-10-23	Upgrade	Piper Sandler	Neutral → Overweight
Sep-28-23	Initiated	Bernstein	Outperform
Aug-02-23	Downgrade	The Benchmark Company	Buy → Hold
May-10-23	Upgrade	Craig Hallum	Hold → Buy
May-05-23	Initiated	UBS	Neutral
Mar-09-23	Upgrade	Citigroup	Neutral → Buy
Feb-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Oct-19-22	Downgrade	Craig Hallum	Buy → Hold
Aug-25-22	Initiated	Credit Suisse	Outperform
Jun-03-22	Initiated	Piper Sandler	Neutral
Nov-03-21	Downgrade	Raymond James	Strong Buy → Outperform
Jul-29-21	Reiterated	BTIG Research	Buy
Jul-29-21	Reiterated	Canaccord Genuity	Buy
Jul-29-21	Reiterated	Oppenheimer	Outperform
Jul-29-21	Reiterated	Stifel	Buy
Jun-15-21	Initiated	Raymond James	Strong Buy
Jun-03-21	Initiated	Goldman	Buy
May-25-21	Initiated	Wells Fargo	Equal Weight
Jan-28-21	Initiated	Truist	Buy
Oct-29-20	Downgrade	UBS	Buy → Neutral
Oct-28-20	Downgrade	Citigroup	Buy → Neutral
Oct-08-20	Resumed	BTIG Research	Buy
Apr-02-20	Initiated	Evercore ISI	Outperform
Jan-10-20	Resumed	BTIG Research	Buy
Jan-07-20	Initiated	Citigroup	Buy
Dec-13-19	Initiated	Dougherty & Company	Buy
Nov-15-19	Initiated	Stifel	Buy
Oct-17-19	Reiterated	BofA/Merrill	Buy
Oct-01-19	Resumed	Craig Hallum	Buy
Sep-26-19	Initiated	Oppenheimer	Outperform
Feb-26-19	Upgrade	Goldman	Neutral → Buy
Oct-09-18	Initiated	UBS	Buy
Sep-05-18	Resumed	The Benchmark Company	Hold
Aug-13-18	Reiterated	Canaccord Genuity	Buy
Apr-03-18	Upgrade	BTIG Research	Neutral → Buy
Jan-29-18	Initiated	Goldman	Neutral
Jan-08-18	Reiterated	The Benchmark Company	Buy
Nov-13-17	Downgrade	Robert W. Baird	Outperform → Neutral
Nov-01-17	Downgrade	BTIG Research	Buy → Neutral

View All

Exact Sciences Corp Stock (EXAS) Latest News

Nov 26, 2024

Exact Sciences stock lifted by TD Cowen, sees 10% revenue growth potential from CG+ - Investing.com Canada

Nov 26, 2024

Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.

Nov 26, 2024

Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED) - AOL

Nov 26, 2024

Exact Sciences stock outlook improves with Cologuard Plus launch and Medicare reimbursement - Investing.com

Nov 26, 2024

Exact Sciences stock rating maintained outperform as Medicare pricing boosts CG+ outlook - Investing.com

Nov 26, 2024

Exact Sciences stock up 10%, BTIG raises target after 16% price increase for Cologuard Plus - Investing.com

Nov 26, 2024

Exact Sciences sees 16% Medicare boost for Cologuard Plus stock, driving FY25 revenue potential - Investing.com

Nov 26, 2024

S&P 500 Futures Climb in Premarket Trading; Woodward, Exact Sciences Lead - Barron's

Nov 26, 2024

Exact Sciences to Participate in December 2024 Investor Conferences - BioSpace

Nov 26, 2024

Exact Sciences to Present at Major Healthcare Investor Conferences in December | EXAS Stock News - StockTitan

Nov 26, 2024

Nov 25, 2024

Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS - TipRanks

Nov 25, 2024

Exact Sciences to Present 10 Key Studies on Breast Cancer Test Effectiveness at SABCS | EXAS Stock News - StockTitan

Nov 25, 2024

Nov 24, 2024

Exact Sciences Co. (NASDAQ:EXAS) Position Trimmed by Victory Capital Management Inc. - MarketBeat

Nov 24, 2024

Nov 22, 2024

B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 32,194 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 22, 2024

Nov 21, 2024

Cathie Wood's ARK buys Tempus AI stock, sells Exact Sciences - Investing.com India

Nov 21, 2024

Swiss National Bank Increases Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 21, 2024

Nov 20, 2024

Madison-based Exact Sciences reports Q3 results short of analysts’ expectations - Chippewa Herald

Nov 20, 2024

EULAV Asset Management Boosts Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat

Nov 20, 2024

Nov 19, 2024

Exact Sciences Corporation (EXAS): Among the Best Genomics Stocks to Buy Right Now - Insider Monkey

Nov 19, 2024